Category Archives: Patently BIOtech

Patenting Genes: NPR Talks IP with BIO

Today, June 4, 2009 at 1:00 PM ET DC’s WAMU Radio Station (88.5 FM) or at  http://wamu.org/programs/kn/09/06/04.php#26424 The genetic material in our cells make us who we are. But since 1982, the U.S. Patent Office has issued tens of thousands of patents to private companies for gene-related products. The biotechnology industry says these patents are necessary to spur innovation. Opponents say they actually stifle science. We examine the intersection of cutting-edge genetic research and intellectual Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

Bloggers Cover IP at the 2009 International Convention

Both Patent Baristas and Patent Docs wrote up some great analyses of the ip sessions at the 2009 BIO International Convention. Visit www.patentbaristas.com and www.patentdocs.net to view their posts on patent reform, biosimilars, healthcare reform, USPTO reform efforts, and more.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

For U.S. Healthcare Reform and Global Health Crises, Both Public and Private Efforts Needed

How can we address health needs in both the United States and developing countries at the same time? By bringing everyone to the table for open, fair, collaborative partnerships. It saves money, time, effort and – most important of all – lives.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

IP Think Tank Podcast: Biotech Intellectual Property at the Crossroads

Thanks to the IP Think Tank blog, we have a great podcast on Biotech Now where Gregory Glover, a panellist at the 2009 BIO International Convention about the pending Biosimilar legislation and concerns over situations where a follow on product might avoid patent claims but still be able to rely on innovator regulatory data.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

China IP Forum to Bring Third Patent Amendment Face-to-Face with Biotechnology Concerns

Emerging markets, particularly the China market, have become a strategic area for pharmaceutical and chemical companies and law firms. China’s lawmakers adopted third revision of the law recently, which will bring a number of substantial changes to the Chinese patent system.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: